BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18357466)

  • 1. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.
    Huang ZH; Hua D; Li LH; Zhu JD
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1129-34. PubMed ID: 18357466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
    Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
    World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer.
    Tominaga T; Iwahashi M; Takifuji K; Hotta T; Yokoyama S; Matsuda K; Higashiguchi T; Oku Y; Nasu T; Yamaue H
    Int J Cancer; 2010 Apr; 126(7):1691-701. PubMed ID: 19810096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
    Oh SY; Kwon HC; Kim SH; Lee S; Lee JH; Hwang JA; Hong SH; Graves CA; Camphausen K; Kim HJ; Lee YS
    BMC Cancer; 2013 Feb; 13():43. PubMed ID: 23374220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
    J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.
    Wang S; Chen L; Zhao Q; Rong H; Wang M; Gong W; Zhou J; Wu D; Zhang Z
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1073-82. PubMed ID: 23423487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma.
    Yashiro M; Inoue T; Nishioka N; Matsuoka T; Boland CR; Hirakawa K
    Ann Surg Oncol; 2009 Oct; 16(10):2926-35. PubMed ID: 19597886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
    Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
    J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer.
    Nakamura J; Kitajima Y; Kai K; Mitsuno M; Ide T; Hashiguchi K; Hiraki M; Miyazaki K
    Oncol Rep; 2009 Oct; 22(4):693-9. PubMed ID: 19724845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
    Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
    Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 Arg72Pro polymorphism in gastric cancer patients.
    Gomes de Souza L; Miranda de Lima J; Dale Cotrim Guerreiro da Silva I; Manoukian Forones N
    J Gastrointest Cancer; 2009; 40(1-2):41-5. PubMed ID: 19543839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
    Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines.
    Endo F; Nishizuka SS; Kume K; Ishida K; Katagiri H; Ishida K; Sato K; Iwaya T; Koeda K; Wakabayashi G
    PLoS One; 2014; 9(2):e90155. PubMed ID: 24587255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
    Büyükçelik A; Onur H; Akbulut H; Bülent Y; Ensari A; Utkan G; Onal BS; Içli F
    Tumori; 2005; 91(4):302-8. PubMed ID: 16277093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.